Back to Search Start Over

Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.

Authors :
Light N
Layeghifard M
Attery A
Subasri V
Zatzman M
Anderson ND
Hatkar R
Blay S
Chen D
Novokmet A
Fuligni F
Tran J
de Borja R
Agarwal H
Waldman L
Abegglen LM
Albertson D
Finlay JL
Hansford JR
Behjati S
Villani A
Gerstung M
Alexandrov LB
Somers GR
Schiffman JD
Rotter V
Malkin D
Shlien A
Source :
Nature communications [Nat Commun] 2023 Jan 05; Vol. 14 (1), pp. 77. Date of Electronic Publication: 2023 Jan 05.
Publication Year :
2023

Abstract

Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53, with gain of the mutant allele. This occurs earlier in these tumors compared to tumors with somatic TP53 mutations, suggesting the timing of this mark may distinguish germline from somatic TP53 mutations. Phylogenetic trees of tumor evolution, reconstructed from bulk and multi-region WGS, reveal that LFS tumors exhibit comparatively limited heterogeneity. Overall, our study delineates early copy number gains of mutant TP53 as a characteristic mutational process in LFS tumorigenesis, likely arising years prior to tumor diagnosis.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
2041-1723
Volume :
14
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
36604421
Full Text :
https://doi.org/10.1038/s41467-022-35727-y